FDA grants Fast Track Designation (FTD) to PVSRIPO for treatment of advanced melanoma

FTD for this investigational immunotherapy based on the live attenuated Sabin type 1 poliovirus vaccine, was granted for use in patients who have disease progression after anti-PD-1/anti-PD-L1 therapy. Multiple trials are underway in combination with anti-PD-1/L1 therapies

Source:

Biospace Inc.